Skip to content

Group Cognitive Behavioural Family Intervention (CBFI) for People With Schizophrenia and Their Families

Effectiveness of Group Cognitive Behavioural Family Intervention (CBFI) for People With Schizophrenia and Their Families: A Mixed-method Study

Status
Withdrawn
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04065360
Enrollment
0
Registered
2019-08-22
Start date
2021-01-31
Completion date
2022-12-31
Last updated
2023-03-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psychosis, Schizophrenia

Keywords

Schizophrenia, Psychosis, Family intervention, Cognitive behavioural therapy, CBT

Brief summary

Cognitive behavioural family intervention (CBFI) is a brief psychosocial intervention that incorporates the model of cognitive behavioural therapy (CBT) into the family context. It builds upon the current trend of family interventions/psychoeducation with refocusing on the cognitive model within the family interpersonal relationship. Existing literature indicates that CBFI may be effective in improving positive and negative symptoms of people diagnosed with schizophrenia immediately following the programme. This mixed-method is to evaluate the feasibility and effectiveness of a CBFI programme for people with schizophrenia and their families in a local context. The findings may accumulate more evidence that CBFI is a brief and effective psychosocial intervention that is adapted to Hong Kong clinical settings.

Interventions

BEHAVIORALGroup Cognitive behavioural family intervention (CBFI)

four-week, four-session CBT-based family intervention programme

BEHAVIORALUsual group psychoeducation

Treatment as usual in the institution studied

Sponsors

The University of Hong Kong
CollaboratorOTHER
Hospital Authority, Hong Kong
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

Service users * Diagnosis of schizophrenia-spectrum disorders, based on clinical judgement by the treating clinicians * Aged 18-65 * Able to communicate in Cantonese Family caregivers * Aged above 18 * Living with service users * Able to communicate in Cantonese * Nominated by the service users

Exclusion criteria

Service users * Having co-morbidity of learning disability * Organic/neurological conditions * Substance misuse disorder Family caregivers * Having active psychiatric conditions * Looking after more than one family member suffering from chronic physical or mental illnesses

Design outcomes

Primary

MeasureTime frameDescription
Qualitative feedback from the clinicians of the concerned wardsImmediate posttreatmentProgramme evaluation interview

Secondary

MeasureTime frameDescription
Negative symptoms of service usersImmediate posttreatmentBrief Negative Symptom Scale (BNSS); 13-item ranging from 0 to 78
Expressed emotion by service usersImmediate posttreatmentConcise Chinese Level of Expressed Emotion Scale (CCLEES); 12-item ranging from 12 to 48
Caregiving experience by family caregiversImmediate posttreatmentChinese version of Experience of Caregiving Inventory (CECI); 66-item ranging from 0 to 264
Positive symptoms of service usersImmediate posttreatmentPsychotic Symptoms Rating Scales (PSYRATS); 11-item hallucination subscale ranging from 0 to 44; 6-item delusion subscale ranging from 0 to 24
Mood disturbance by family caregiversImmediate posttreatmentHospital Anxiety and Depression Scale (HADS); 7-item depression subscale ranging from 0 to 21; 7-item anxiety subscale ranging from 0 to 21
Qualitative feedback from the service users and their familiesImmediate posttreatmentSemi-structured focus group interview
Perceived care burden by family caregiversImmediate posttreatmentFamily Burden Interview Schedule (FBIS); 25-item ranging from 0 to 50

Countries

Hong Kong

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026